论文部分内容阅读
以健康人群为对照 ,Graves病患者分成甲巯咪唑 (MMI)组 (MMI 2 0mg/d)和甲氨蝶呤(MTX)组 (MMI 2 0mg/d +MTX 7.5mg/w ) ,测得患者组CD4、Th增高而Tc低下 ,治疗 6周后该异常虽无明显改变 ,可溶性白细胞介素 2 (sIL 2 )受体和甲状腺自身抗体下降 ,但组间差异无显著性。提示Graves病治疗前存在免疫异常 ,MMI及其加用MTX治疗 6周使sIL 2受体及甲状腺自身抗体明显下降 ,加用MTX未见对免疫功能的影响优于单用MMI。
Patients with Graves disease were divided into two groups: MMI group (MMI 20 mg / d) and methotrexate group (MMI 20 mg / d + MTX 7.5 mg / w) The levels of CD4, Th increased and Tc decreased. After six weeks of treatment, the abnormalities did not change. The levels of soluble interleukin 2 receptor (sIL 2) and thyroid autoantibodies decreased, but there was no significant difference between groups. Suggesting that there is an immune abnormality before treatment of Graves disease. MMI and MTX combined with MTX for 6 weeks reduced sIL 2 receptor and thyroid autoantibodies significantly, and the effect of adding MTX on immune function was superior to single MMI.